
HealthCap is a well-established venture capital fund that has been investing in life science companies since 1999. The fund has a strong track record of supporting innovative companies.
HealthCap's portfolio includes a diverse range of life science companies across various stages of development.
HealthCap has invested in companies such as BioInvent, a Swedish biotech company that specializes in antibody-based treatments.
For another approach, see: Co-founder Animoca Brands - Yat Siu
Co-Investors
Co-investors play a significant role in HealthCap's portfolio companies. Over the past 27 years, 373 investors have co-invested in these companies.
HealthCap doesn't go it alone, and that's a good thing. Many investors have invested in rounds before HealthCap, including Versant Ventures and Sofinnova Partners, which have invested in 2 and 2 companies respectively before partnering with HealthCap.
Some investors are more frequent co-investors than others. Novo Holdings, for example, has co-invested with HealthCap in 8 companies.
HealthCap also co-invests with investors who come in after their initial investment. A total of 159 investors have done just that, including Rock Springs Capital, which has co-invested with HealthCap in 4 companies.
Here are some of the top co-investors of HealthCap:
- Novo Holdings (8 companies)
- Rock Springs Capital (4 companies)
- Adage Capital Management (3 companies)
- Orbimed (3 companies)
Sectors of Investment

HealthCap's investment strategy is quite diverse, and it's interesting to see where they focus their efforts.
HealthCap has made a significant number of investments in the Life Sciences sector, with a total of 56 investments.
One of the sectors that HealthCap invests in is High Tech, but it's worth noting that they have made relatively fewer investments in this area, with only 8 investments.
HealthCap also invests in Healthcare, with a total of 7 investments.
In addition to these sectors, HealthCap has also made investments in Sustainability Tech, with a total of 4 investments.
HealthCap's investment portfolio includes a mix of sectors, and it's clear that they're not afraid to take calculated risks.
Here's a breakdown of the sectors where HealthCap has made investments:
Portfolio Details
HealthCap's portfolio includes a mix of acquired companies and public companies. The acquired companies in HealthCap's portfolio include Fusion Pharmaceuticals, ChemoCentryx, Strongbridge Biopharma, Five Prime Therapeutics, and Ultragenyx.
These companies have been acquired at various dates, with the earliest being ChemoCentryx in 2022 and the most recent being Fusion Pharmaceuticals in 2024. HealthCap first invested in these companies at different times, ranging from 2004 to 2017, with the first round of investment varying from Series A to Post IPO.
Here are some key details about the acquired companies:
Investments and Portfolio Companies

Healthcap's portfolio is made up of a diverse range of companies, each with its own unique story and investment history. We'll take a closer look at some of the companies in their portfolio.
Onxeo, a biotech company, went public on December 15, 2020. Spruce Biosciences, another biotech company, also went public on October 9, 2020, after first being invested in on February 19, 2020, with a Series B round of $88 million. Spruce was later re-invested in on February 9, 2023, in a post-IPO deal.
Pulmonx, a medical device company, went public on October 2, 2020, after first being invested in on April 30, 2010, with a Series C round of $33.6 million. Aprea, a biotech company, went public on October 4, 2019, after first being invested in on March 9, 2016, with a Series B round of $50.7 million.
Here's a breakdown of the IPO dates and first investment rounds for some of the companies in Healthcap's portfolio:
Companies in Portfolio

HealthCap has a diverse portfolio of companies across the healthcare industry.
One notable company in their portfolio is Fusion Pharmaceuticals, which they acquired in March 2019. Fusion Pharmaceuticals was first invested in back in 2017.
HealthCap has also invested in ChemoCentryx, a company they acquired in August 2022. ChemoCentryx was first invested in all the way back in 2004.
Another company in their portfolio is Strongbridge Biopharma, which they acquired in May 2021. Strongbridge Biopharma was first invested in post-IPO in 2014.
In addition to these companies, HealthCap has also invested in Five Prime Therapeutics, which they acquired in March 2021. Five Prime Therapeutics was first invested in 2005.
Lastly, HealthCap has invested in Ultragenyx, a company they acquired in December 2019. Ultragenyx was first invested in 2011.
Here's a list of some of the notable companies in HealthCap's portfolio:
Financials
HealthCap has a strong financial foundation, with a total committed capital of $1.3 billion as of 2022. This significant investment allows them to support innovative life science companies.

Their fund size has grown steadily over the years, with a first fund launched in 2000 and subsequent funds established in 2006 and 2011. This growth has enabled HealthCap to invest in a wide range of companies.
HealthCap's focus on life sciences has led to a strong track record of returns, with an IRR of 23% over the past 20 years. This performance is a testament to their expertise in the sector.
Their investments have also led to significant exits, including the acquisition of companies like Cellavista and Olink Bioscience. These exits have generated substantial returns for investors.
HealthCap's financial stability and expertise in life sciences make them an attractive partner for innovative companies in the sector.
History and Team
HealthCap is a venture capital firm with a rich history. Founded in 1999, it has been investing in life sciences companies for over two decades.
The team behind HealthCap is comprised of experienced professionals with a deep understanding of the life sciences industry. They have a proven track record of identifying and supporting innovative companies that have the potential to make a significant impact.
Strategy

HealthCap's investment strategy is built around achieving significant capital appreciation by focusing on diseases with a high unmet medical need and breakthrough therapies.
The team takes pride in its active involvement in portfolio companies, with one or more team partners taking board seats and leveraging their extensive scientific and industrial networks for recruitment of experienced professionals.
Precision medicine is a cornerstone of HealthCap's strategy, aiming to develop the right medicine for the right patient, which is made possible by the rapid pace of innovation in the field.
HealthCap has substantial experience in helping start-ups and emerging companies grow into businesses ready for initial public offerings or trade sales, ensuring long-term sustainability for the portfolio companies.
Expand your knowledge: Perella Weinberg Partners Industrials Team New Yor
VC Fund History
Our VC fund has a rich history that dates back to 2015, when it was first established with a seed funding of $10 million.
The fund's early success was driven by the team's ability to identify and invest in innovative startups, such as GreenTech, a company that developed sustainable energy solutions.

In 2018, the fund received a significant boost with an additional $50 million in funding, which enabled it to expand its portfolio to include more established companies.
The team's expertise in identifying high-growth potential companies has been a key factor in the fund's success, with a notable example being the investment in HealthCare, a company that developed a cutting-edge medical device.
The fund's focus on innovation and risk-taking has allowed it to stay ahead of the curve and capitalize on emerging trends, such as the growth of the e-commerce industry.
One notable example of the fund's e-commerce investments is the company, RetailTech, which developed an AI-powered retail platform.
The team's ability to adapt to changing market conditions and pivot investments when necessary has also been a key factor in the fund's success, as seen in the case of the investment in FinTech, a company that developed a mobile payment solution.
Additional reading: Summit Growth Partners
Managing Partner
Marten Steen is the Managing Partner of HealthCap. He plays a crucial role in the company's decision-making process.
HealthCap has a strong leadership team, and Marten Steen is a key member. His expertise and experience have been instrumental in shaping the company's vision and strategy.
Employment and Codes

HealthCap's employment opportunities are designed to support the growth and well-being of its employees. They offer a comprehensive benefits package that includes health insurance and retirement savings plans.
HealthCap's employees are required to adhere to a strict code of conduct, which emphasizes honesty, integrity, and respect for others. This code is outlined in the company's employee handbook.
As a result, HealthCap has a reputation for being a trustworthy and reliable organization in the industry.
How Many People Are Employed?
Employment and Codes are closely tied, but let's start with a basic question: How many people are employed at HealthCap? 20 people are employed at HealthCap.
Working at a small company like HealthCap can be a great experience, but it's not the same as working at a large corporation. Some companies have a few employees, while others have thousands.
For example, HealthCap has a relatively small team of 20 people. This can make for a more personal and collaborative work environment.
On a similar theme: Angel Investors for Small Business
What Is the SIC Code?

The SIC code is a crucial piece of information in the employment world.
HealthCap has a SIC code of 283 and 28.
The SIC code for HealthCap is a specific classification that helps identify the industry.
These codes are used for various purposes, including job searching and company research.
For example, if you're searching for job openings, you might look for companies with a SIC code of 283 or 28.
Featured Images: pexels.com


